Significant improvement in asthma control test (C-ACT) scores in children treated with long-term low-dose ICS compared to those with shorter treatment durations.
Significant improvements in FEV1, FVC, and ACT scores, along with a decrease in asthma exacerbations, hospitalizations, and emergency room visits after one year of treatment.
Clinical remission rates ranged from 28.6% to 43.2% after 12 months and from 26.8% to 52.9% after 24 months. Sustained remission was achieved by 14.6% to 29% of patients, highlighting the long-term effectiveness of mepolizumab.
The study found no significant difference in treatment failure rates between adrenaline and selective beta-2-agonists, suggesting similar efficacy in managing acute asthma.
Both tezepelumab and dupilumab significantly reduce exacerbations and improve lung function (FEV1) in patients with eosinophilic asthma compared to placebo.
Vaccination generally leads to the production of antibodies and T cells against SARS-CoV-2, but the study found that a significant portion of patients with chronic lung diseases had reduced immune responses compared to healthy controls.
Significant improvements in asthma control test scores, reduction in annual exacerbation rates, and decreased blood eosinophil counts were observed. Patients also showed a reduction in daily oral corticosteroid intake after 12 months of treatment.
Patients with higher ACT scores were more likely to remain on mepolizumab therapy, while those with scores below 13 had a significantly higher risk of discontinuation.
Higher adherence to ICS was associated with better symptom control and improved HRQoL over time. Better inhalation technique correlated with improved HRQoL in future assessments, despite worse HRQoL at the time of assessment.
Both ICS monotherapy and ICS/LABA were effective in improving asthma control, with significant reductions in the use of short-acting beta-agonists and the number of nebulisations in patients on ICS monotherapy. Close monitoring and communication were found to positively impact asthma control.
Significant changes in gene expression and DNA methylation were observed in responders, with unique gene expression profiles identified that may predict long-term clinical response to Mepolizumab.
The study identifies 36 novel SNPs associated with asthma that are located in eRNA-transcribing regions. These findings suggest a link between air pollution, glucocorticoid signaling, and asthma, providing insights into the genetic factors that may influence treatment responses and disease susceptibility.
Participants showed significant improvement in asthma control, with a median increase of 2.39 points on the Asthma Control Test (ACT). 86% learned about new asthma triggers, and 75% felt more empowered to manage their asthma, leading to improved quality of life.
The study found that early-onset asthma patients with the G allele of the rs2660845 variant had an increased risk of asthma exacerbations despite montelukast treatment, suggesting that genetic factors can influence treatment efficacy.
The study found that 49.6% of patients had controlled asthma, indicating that effective management strategies can lead to better outcomes. However, over half of the patients (50.4%) had uncontrolled asthma, highlighting the need for improved treatment adherence and awareness.
The study identified enablers for better asthma management, including improved education for doctors and the general population, as well as better access to diagnostic tests and medications, which could lead to better adherence to GINA recommendations.
Improved understanding of drug deposition patterns in different patient populations, leading to optimized inhaler techniques and potentially better therapeutic outcomes during respiratory exacerbations.
The protocol aims to reduce unplanned hospital admissions, enhance patient management, and improve overall health outcomes for patients with chronic pulmonary diseases.
The study found that experiencing a first severe asthma exacerbation significantly increased the rate of subsequent exacerbations, with a 79% increase in pediatric patients and 186% in adult patients, highlighting the importance of preventing further exacerbations to reduce future risks.
The study found a significant decrease in pediatric asthma patients during the COVID-19 pandemic, indicating a potential reduction in asthma exacerbations and hospital visits during this period.
Participants in the intervention group reported significantly improved asthma-related quality of life compared to baseline, with a non-significant trend favoring the intervention group over the control group at the 3-month follow-up.
Effective management of acute paediatric asthma can lead to reduced hospital admissions, improved respiratory function, and better overall patient outcomes.
Asthmatic subjects showed significant improvements in lung function and serum short-chain fatty acid levels after four weeks of treatment.
The vaccination elicited SARS-CoV-2-specific humoral and cellular immunity, although this immunity significantly declined 6 months after the second dose. The type of biological treatment did not affect the vaccine-elicited immunity.
Identification of three distinct cytokine modules associated with asthma severity and immune signaling, leading to potential personalized treatment strategies based on sputum cytokine profiles.
The identification of a novel genetic locus associated with early-onset persistent wheeze and the potential for targeting the ANXA1 pathway may lead to new therapeutic strategies for managing persistent wheezing in children.
The study found that apoptosis is involved in regulating airway contractile cell turnover, contributing to the proper size, structure, and function of the airway smooth muscle layer. Increased apoptotic activity was associated with limited airway contractile tissue growth.
Cytokine levels in nasal lavage fluid showed moderate to very good discrimination performance for detecting viral infections, qualifying them for disease progression monitoring.
Expected improvements in asthma control, quality of life, and pulmonary function variables in patients receiving IFT alongside bronchodilator therapy.
Improved medication deposition in the lungs, enhanced patient outcomes, and reduced healthcare costs through effective inhaler use. The study aims to inform policy decisions for sustainable healthcare solutions.
The integration of capnography with CPAP therapy allows for better monitoring of respiratory parameters, potentially leading to improved patient outcomes by enabling timely interventions and reducing the need for intubation.
Participants reported improvements in physical, psychological, and social health, with a willingness to continue exercising at home after the program.
Dupilumab treatment led to a significant reduction in type 2 associated cytokines (TSLP, IL-5, eotaxin-3) and distinct changes in the transcriptomic profile during ASA provocation, indicating a dampened type 2 response.
The study identifies significant gene-metabolite associations that may help in understanding the biological pathways influencing total IgE levels, potentially leading to improved treatment strategies for pediatric asthma.
The study found that RSV immunoprophylaxis during infancy significantly impacted DNA methylation patterns in nasal cells at age 6, with implications for long-term immune response and potential asthma development.
Increased eosinophil and lymphocyte counts in BAL fluid after allergen challenge. GSTM1-null subjects showed reduced inflammatory responses, including lower eosinophil and IL-4 responses to allergen after ozone exposure.
The expected positive outcomes include improved pulmonary function parameters (FEV1, FVC, PEFR), enhanced CAT scores, and better performance in the 6MWT among patients with obstructive, restrictive, or mixed ventilatory impairments.